Replimune to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Replimune Group, a clinical stage biotechnology company specializing in tumor-directed oncolytic immunotherapies, announced its participation in two upcoming investor conferences. The BTIG Biotechnology Conference will take place on August 8, 2022, featuring a fireside chat at 11:00 am ET. The company will also present at the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, with a fireside chat scheduled for 9:45 am ET. A live webcast will be available on Replimune's website.

WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

BTIG Biotechnology Conference 2022
Date: Monday, August 8, 2022
Fireside Chat Time: 11:00 am ET

2022 Wedbush PacGrow Healthcare Virtual Conference
Date: Wednesday, August 10, 2022
Fireside Chat Time: 9:45 am ET

A live webcast and replay of the fireside chat at 2022 Wedbush PacGrow Healthcare Conference will also be available in the Investors section of Replimune’s website at www.replimune.com.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com

FAQ

When is Replimune presenting at the BTIG Biotechnology Conference?

Replimune will present at the BTIG Biotechnology Conference on August 8, 2022, at 11:00 am ET.

What is the date and time for Replimune's presentation at the Wedbush PacGrow Healthcare Virtual Conference?

Replimune's presentation at the Wedbush PacGrow Healthcare Virtual Conference is set for August 10, 2022, at 9:45 am ET.

Where can I watch the Replimune webcast for the Wedbush Conference?

The webcast for Replimune's presentation at the Wedbush Conference will be available in the Investors section of their website.

What is Replimune's focus in biotechnology?

Replimune focuses on developing novel tumor-directed oncolytic immunotherapies to transform cancer treatment.